Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2017 | The impact of antiemetics

Matti Aapro • 8 Sep 2017
ESMO 2017
NEPA

Matti Aapro, MD, from the Multidisciplinary Oncology Institute, Genolier, Switzerland, discusses the development of new antiemetics at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. New antiemetics have been developed, for example, NEPA, a combination of an NK receptor antagonist and palonosetron. The development of these will have a big impact on the quality of life of patients.

More from Matti Aapro

Supportive care in cancer: more is needed
3:39
Supportive care in cancer: more is needed
Matti Aapro • 28 Sep 2019
NEPA to prevent chemotherapy-induced nausea and vomiting
2:15
NEPA to prevent chemotherapy-induced nausea and vomiting
Matti Aapro • 28 Sep 2019
How to manage elderly patients on immunotherapy
3:14
How to manage elderly patients on immunotherapy
Matti Aapro • 18 Jan 2019
Guidelines for adherence to CINV treatment
2:47
Guidelines for adherence to CINV treatment
Matti Aapro • 4 Jan 2019

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals